In this issue of Hematology/Oncology Clinics, guest editors Drs. Jorge J. Castillo, Prashant Kapoor, and Shayna Sarosiek bring their considerable expertise to the topic of Waldenström Macroglobulinemia. Top experts in the field provide a focused update on the biology, diagnosis and management, and novel therapies for patients with Waldenström macroglobulinemia, a rare blood cell cancer characterized by an excess of abnormal white blood cells in the bone marrow. Contains 14 practice-oriented topics including clinical implications of genomic profile in Waldenström macroglobulinemia; chemoimmunotherapy regimens in the frontline management of Waldenström macroglobulinemia; management of relapsed or refractory Waldenström macroglobulinemia; evaluation and management of aggressive transformation in Waldenström macroglobulinemia; management of Waldenström macroglobulinemia in limited-resource settings; and more.  Provides in-depth clinical reviews of Waldenström macroglobulinemia, offering actionable insights for clinical practice.  Presents the latest information on this timely, focused topic under the leadership of experienced editors in the field. Authors synthesize and distill the latest research and practice guidelines to create clinically significant, topic-based reviews. 

This book focuses expressly on model organisms for lymphoma, the in-depth coverage provided has been edited by an acknowledged academic authority on the topic. The material details every factor informing judgments on prognosis.

This issue of Hematology/Oncology Clinics, edited by Drs. Jorge J. Castillo, Steven P. Treon, and Stathis Kastritis, will focus on Waldenstrom Macroglobulinemia. Topics include, but are not limited to, Genomics; Epigenomics; Flow cytometry; Marrow microenvironment; Familial Waldenstrom; MYD88 L265P and other MYD88 mutations; CXCR4 and other recurrent mutations; Diagnosis and differential diagnosis; Criteria to treat and treatment goals; Alkylators; Monoclonal antibodies; Proteasome inhibitors; BTK inhibitors; Transplant; and Novel approaches.

This book will be the first that focuses on solely on model organisms for lymphoma. It's editors are internationally recognized in the field.

Plasmablastic lymphoma was initially described in 1997 associated with infection with HIV. This lymphoma usually presents within the oral cavity of HIV-infected individuals and carries a poor prognosis with current chemotherapeutic approaches. Given its rarity, with just over 200 hundred patients reported in the literature to date, prospective studies are unlikely to be undertaken. With the emergence of this lymphoma, more cases are being identified in HIV-negative patients. The present publication reviews the current knowledge on the pathogenesis, clinicopathological characteristics, prognostic factors and management of plasmablastic lymphoma.